Ensysce Biosciences announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company’s common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules. In addition, in a concurrent private placement, the Company issued warrants to purchase up to 3,571,431 shares of common stock. The warrants have an exercise price of $0.715 per share, are exercisable immediately following issuance and will have a term of five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering were approximately $3.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include funding capital expenditures and working capital and repaying indebtedness.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENSC:
- Ensysce Biosciences announces $3M registered direct offering
- Ensysce Biosciences initiates final stage of Phase 1 study of PF614-MPAR
- Ensysce CEO says ‘highly focused’ on execution of clinical development timeline
- Ensysce completes clinical portion of oral human abuse potential trial
- Ensysce Biosciences announces data from PF614-MPAR-101 Part A trial